Prof. Sun Zimin: The 16th National Leukemia and Lymphoma Academic Conference of the Chinese Medical Association was brilliant, and the future of leukemia diagnosis and treatment can be expected!

October 8-10, 2021, hosted by the Chinese Medical Association, Chinese Medical Association Hematology Branch, Chinese Medical Association Hematology Branch Leukemia and Lymphoma Group, Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) The 16th National Leukemia and Lymphoma Academic Conference of the Chinese Medical Association hosted by the First Affiliated Hospital of the University of Science and Technology of China was successfully held in Hefei, Anhui Province
.

At the closing ceremony of the conference, Yimaitong was honored to invite Professor Sun Zimin from the First Affiliated Hospital of University of Science and Technology of China, chairman of the conference, to share with him the highlights of the conference and the progress of leukemia diagnosis and treatment
.

Yimaitong: As one of the chairpersons of the 16th National Leukemia and Lymphoma Academic Conference of the Chinese Medical Association, would you please introduce the highlights of this conference? Professor Sun Zimin This conference is a grand meeting of hematology.
In the post-epidemic era, domestic and foreign experts and colleagues gathered together to share an academic feast and jointly discussed the development and future of hematology
.

Highlights of this conference were numerous, including: 1) The conference had a large number of offline participants, and nearly 500 people arrived at the opening ceremony; 2) The conference carefully selected the submissions from various units across the country and selected the latest Sharing of innovative and innovative topics; 3) The meeting set up a special session for continuing education, mainly focusing on leukemia topics, whether it is common acute myeloid leukemia, acute lymphoblastic leukemia, etc.
, or uncommon hairy cell leukemia, Mast cell leukemia, etc.
, all have more detailed special lectures; 4) The meeting set up a CAR-T cell technology special session, introducing the latest progress of CAR-T cells in the treatment of leukemia and lymphoma, including treatment plans, treatment effects, and complications 5) In addition, after a lapse of four years, the 2021 China Acute Myeloid Leukemia Diagnosis and Treatment Guidelines Release Conference will also be held at this conference; 6) This conference has also successfully held the annual blood clinic At the thinking contest, at the scene of the competition, young doctors had a skill "competition" and a "collision" of thinking, which was wonderful
.

In general, this conference has benefited the participants a lot, and it can be described as a grand event for leukemia and lymphoma
.

Yimaitong: At this conference, the content related to leukemia diagnosis and treatment was wonderful.
Could you please introduce the current status of leukemia diagnosis and treatment, and talk about your prospects for leukemia diagnosis and treatment in the future? Professor Sun Zimin’s leukemia incidence rate is three to nine per 100,000, which is a disease that seriously endangers the health of patients
.

Among young and middle-aged patients under the age of 35, the incidence of leukemia is the most malignant disease
.

Therefore, it is very important for patients' families and society to carry out standardized diagnosis and treatment of leukemia to further improve the curative effect
.

The diagnosis and treatment of leukemia is systematic.
With the continuous update of morphological testing and genetic testing, the diagnosis of leukemia has become more and more accurate.
After accurate diagnosis, comprehensive risk stratification and prognosis assessment are required, and then different Method of treatment
.

Standardized and standardized chemotherapy is currently the main method of first-line induction therapy for acute myeloid leukemia.
After successful induction therapy, according to the genetic prognosis risk stratification, different consolidation treatment options are selected
.

For the good prognosis group, high-dose cytarabine-based chemotherapy can be selected; for the moderate and poor prognosis group, allogeneic hematopoietic stem cell transplantation can be performed after the first remission, with the goal of enabling patients to survive for a long time
.

In recent years, with the influx of targeted drugs such as demethylation drugs, FLT3 inhibitors, and BCL-2 inhibitors, many patients can use targeted drugs combined with chemotherapy to further improve the remission of induction therapy.
Rate
.

In addition, in recent years, elderly patients with acute myeloid leukemia can survive long-term after treatment.
For elderly patients who cannot tolerate high-dose chemotherapy regimens, targeted drugs combined with low-dose cytotoxic drugs can also be used for treatment
.

New targeted drugs have better efficacy.
In the future, more new targeted drugs may be included in the first-line induction treatment program to further improve the efficacy
.

Although leukemia is a malignant tumor, it can be cured, and its curative effect is even better than some solid tumors
.

At present, patients with standard-risk acute promyelocytic leukemia no longer need chemotherapy, and long-term survival can be achieved only by treatment with arsenic and retinoic acid
.

In the future, the prospect of leukemia treatment is very bright.
With the continuous advent of new drugs, it is expected that leukemia can be cured without chemotherapy or transplantation
.

Professor Sun Zimin Chief Physician, Professor, Doctoral Supervisor, Department of Hematology, The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) Anhui Province Academic Technology Leader Anhui Province 115 Industrial Innovation Team "Hematopoietic Stem Cell Transplantation" Leader Anhui Province Key Clinical Discipline Disciplinary leader Anhui Provincial Hospital Chief Expert of Hematopoietic Stem Cell Transplantation stamps "read the original text", we make progress together